15th Annual Drug Discovery Summit
-
Day 1 Stream 1: R&D Models For The Future
Compound exchange: collaboration to strengthen pipelines
Open innovation case studies
Reviving existing drug products: increasing therapeutic potential
Practical innovation: what can we learn from biotechs?
Expanding therapeutic areas: pain, anti-addiction
CROs: developing successful partnerships
Day 1 Stream 2: Screening & Assays: Enabling Technologies
Next generation discovery applications
Phenotypic screening vs target-based screening
High content analysis: live cell imaging, 3D cell based assays, flow cytometry
Functional genomics screening
Novel technology platforms: NMR & SPR
iPSC and primary cells: physiologically relevant assays
Day 2 Stream 1: Target Based Discovery
New methods for targeting GPCRs, including allosteric modulator case studies
Target based discovery case studies: rare diseases, protein misfolding disorders, oligonucleotide therapies
Understanding the human kinome
Recent advances in epigenetic drug targets
Targeting Ion channels and PPIs
Macrocycle drugs – opening up new targets?
Day 2 Stream 2: Supporting Innovation: Data & Information Management
Data driven library optimisation
Incorporating development data into discovery research
Legacy data: turning challenge into opportunity
Real time compound annotation: improving drug discovery through data quality
Making the most of discovery data: compound optimisation, dosing regimens and trial design
-
2nd Annual Discovery Chemistry & Drug Design Congress
Day 1 Stream 3: Discovery Chemistry: Latest Case Studies
Fragment based and structure based drug discovery
Analysing structure-activity relationships
Chemical genetic approaches
Hybrid approaches: combining biology and chemistry expertise
Advances in computational chemistry & flow chemistry
The role of natural products in discovery chemistry
Key learnings from ligand binding studies
Day 2 Stream 3: Drug Design: Novel Approaches
Lead optimisation: considering solubility, drugability and potency
Achieving selectivity and specificity
DMPK considerations in lead optimisation
Early de-risking through drug design
Water molecules: assessing the impact on drug discovery and design
Building increased molecular complexity into drug design
Computer aided design for biologics
Please contact Danielle Dalby on d.dalby@oxfordglobal.co.uk to download the full agenda.